Cerebellar glioblastoma: a clinical series with contemporary molecular analysis.

Abstract

BACKGROUND:

Glioblastomas (GBM) are localized in only less than 1% of patients in the cerebellum. Therefore, tumor characteristics, survival, and the efficacy of therapies are not yet well defined. The present study aims to characterize the molecular features of cerebellar GBM (GBMc) in 8 patients treated with contemporary modality in our institution.

METHODS:

Patients' treatment history, progression-free survival (PFS), and overall survival (OS) were analyzed. All histopathological specimens were re-investigated. EGFR amplification was determined by FISH, H3F3A, and HIST1H3B mutation status and MGMT promoter methylation after bisulfite treatment by pyrosequencing and BRAF V600E by pyrosequencing and immunohistochemistry. TERT promoter mutations were analyzed by Sanger sequencing, CDKN2A/B deletions by digital PCR. The expression of IDH1 R132H, ATRX, and p53 was determined through immunohistochemistry.

RESULTS:

Six adults and two children (mean age 36 years) underwent tumor resection via medial or lateral suboccipital craniotomy. The median overall survival (mOS) of the adult patients was 7 months. GBMc from two children demonstrated a H3F3A K27M mutation. One of these also harbored a BRAF V600E mutation and has already had a PFS of 74 months. Mutated IDH1 R132H protein was expressed in 2 GBM from adult patients with previous supratentorial anaplastic astrocytoma. One patient carried a TERT promoter mutation. Another patient initially presented with a thalamic pilocytic astrocytoma. The cerebellar tumor revealed neither a BRAF V600E nor a H3F3A mutation but a homozygous CDKN2A/B deletion.

CONCLUSIONS:

GBM located in the cerebellum can be found in all age groups. We provide novel molecular genetic data on these rare tumors. Mutated IDH1 R132H protein and H3F3A K27M mutations indicate that a substantial number of GBMc are "metastatic" or "diaschismatic" lesions. Mutation of BRAF V600E may have a stronger biological significance than H3F3A K27M alterations. In a subset of patients, GBM may arise primarily as a distinct entity in the cerebellum.

• Authors: Bujung Hong, Rouzbeh Banan, Arne Christians, Makoto Nakamura, Michael Lalk, Ulrich Lehmann, Christian Hartmann, Joachim K Krauss
• Journal: Acta neurochirurgica (Acta Neurochir (Wien)) Vol. 160 Issue 11 Pg. 2237-2248 (11 2018) ISSN: 0942-0940 [Electronic] Austria
• PMID: 30203362 (Publication Type: Journal Article)

Chemical References

• Biomarkers, Tumor
• CDKN2A protein, human
• Cyclin-Dependent Kinase Inhibitor p16
• TP53 protein, human
• Tumor Suppressor Protein p53
• Isocitrate Dehydrogenase
• IDH1 protein, human
• BRAF protein, human
• Proto-Oncogene Proteins B-raf
• TERT protein, human
• Telomerase
• ATRX protein, human
• X-linked Nuclear Protein

Topics

• Adult
• Biomarkers, Tumor (genetics)
• Brain Neoplasms (genetics, pathology)
• Child
• Cyclin-Dependent Kinase Inhibitor p16 (genetics)
• Female
• Glioblastoma (genetics, pathology)
• Humans
• Isocitrate Dehydrogenase (genetics)
• Male
• Middle Aged
• Mutation
• Proto-Oncogene Proteins B-raf (genetics)
• Telomerase (genetics)
• Tumor Suppressor Protein p53 (genetics)
• X-linked Nuclear Protein (genetics)